See highlights from GHTC's 2023 Innovating for Impact Awards

Search the GHTC website

What’s ahead on the Hill: An update on the government shutdown and global health R&D programs

Read time:

In this guest post, Jenny Howell—senior policy & advocacy associate at PATH working with the GHTC—writes about how the government shutdown and budget negotiations in Congress will impact global health research and development (R&D) programs across the federal government.

October 1, 2013 by Jenny Howell

In this guest post, Jenny Howell—senior policy & advocacy associate at PATH working with the GHTC—writes about how the government shutdown and budget negotiations in Congress will impact global health research and development (R&D) programs across the federal government. She also provides an update on new legislation that would impact the President’s Emergency Plan for AIDS Relief (PEPFAR).

It’s been a hectic few weeks in Washington. When House Majority Leader Eric Cantor (R-VA) canceled last week’s scheduled recess—and lawmakers from both chambers stayed to work over the weekend—we hoped that policymakers could successfully prevent a government shutdown.

Because members of Congress have been unable to agree on long-term budget deals, funding for the government has been based on short-term continuing resolutions (CR)—stopgap budgets that fund the government for a few months at a time. The last short-term deal, passed in March, funded the government through the end of September, requiring Congress to pass a new CR by midnight on September 30 or face a federal shutdown.

What the shutdown means in practical terms varies across the government--from Congress to agencies such as USAID, NIH, CDC, and FDA.
What the shutdown means in practical terms varies across the government--from Congress to agencies such as USAID, NIH, CDC, and FDA.

The past week has been a Ping-Pong between competing House and Senate budget bills, with Republicans in the House insisting on a CR that is coupled with the defunding or delay of the Affordable Care Act. Senate leaders, on the other hand, pledged that they will only consider a “clean CR,” or a bill that doesn’t contain major policy changes but only deals with funding. What the shutdown means in practical terms varies across the government.

Congress

On the Hill, it’s up to lawmakers to determine which staffers serve essential functions and which staffers are non-essential. Therefore, staffing will vary greatly from office-to-office.

USAID

The US Agency for International Development (USAID) issued a guidance outlining a few possible scenarios, but indicated that the majority of its contracts and grants are not dependent on new appropriations and will continue operations. The agency has promised to contact partners who have grants or contracts that will be directly impacted by the government shutdown. While most ongoing programs should remain safe with existing funding, this also means USAID won’t be investing in any new R&D funding, contracts, or grants until a budget deal is reached.

HHS

The Department of Health and Human Services (HHS) has also released its contingency plan in the case of a shutdown. The National Institutes of Health (NIH) will continue caring for patients in current clinical centers. However, health research will be severely impacted as NIH will not accept new patients for clinical research. This is on top of an already exhausted post-sequestration budget that NIH Director Dr. Francis Collins has described as delaying innovation.

The Centers for Disease Control and Prevention (CDC) will continue to operate its 24/7 operations center, as well as activities funded through mandatory spending like PEPFAR, the Global AIDS program, and the Vaccines for Children program. The shutdown does impact CDC’s ability to support the annual flu program and much of its ongoing disease surveillance and R&D activities.

The Food and Drug Administration (FDA) will continue activities related to critical public health issues, but will cease the majority of lab research, routine inspections, monitoring, and notification programs. The FDA will continue the majority of its programs linked to user fees, including product approvals, but approval times may be delayed as a result of understaffing.

Moving on PEPFAR

Amidst the tension of the budget battle, members of Congress have seemingly found something they agree on. On September 24, Sens. Robert Menendez (D-NJ) and Bob Corker (R-TN) introduced The PEPFAR Stewardship and Oversight Act of 2013 (S 1545). A day later, Reps. Eliot Engel (D-NY), Ed Royce (R-CA), Barbara Lee (D-CA), and Ileana Ros-Lehtinen (R-FL) introduced a companion bill in the House (HR 3177)

Most of the PEPFAR program can continue to operate as long as Congress appropriates funds. However, some components—mostly reporting requirements—could end without renewal. The bill introduced last week is by no means a full reauthorization and is extremely limited in scope, only extending the PEPFAR program as it relates to HIV and AIDS with no specific extension of tuberculosis (TB) or malaria programming or funding. PEPFAR currently supports a variety of global health R&D projects, including research on microbicides and vaccines for HIV and AIDS, TB, and malaria.

Bill status

The bill is already moving quickly and with the addition of a short manager’s amendment, it was approved by the Senate Committee on Foreign Relations by voice vote earlier this week. The manager’s amendment added reporting requirements to include reporting on co-infections and co-morbidities of HIV and AIDS, including TB, as well as country efforts to improve health work force issues.

The government shutdown makes next steps for the bill uncertain, but the strong bipartisan support makes it likely that leadership in both chambers will fast track the bill and bring it up for consideration without additional amendments.

Looking ahead

We hope support for PEPFAR isn’t the only thing Congress can come to an agreement on this week. While uncertainty about the impact of the shutdown remains high, the quicker that lawmakers can reach an agreement the less severe the negative effects will be across our nation and around the world. Whatever the outcome, we’ll continue to track the progress and its potential impact on global health R&D.

Categories: PEPFAR, US budget

About the author

Jenny HowellGHTC

Jenny Howell is a senior policy and advocacy associate at GHTC, leading the coalition's US Congressional advocacy.

Other Breakthroughs Blog posts you may like:
PATH/Evelyn Hockstein
October 1, 2013

How did health research fare at the UN General Assembly?

Written by Kaitlin Christenson / GHTC
Read time:
  After a busy week of negotiating police barricades and security checks in New York during the United Nations General Assembly (UNGA), we’re back in Washington, DC, with more thinking about the post-2015 development agenda and some reflections about what was heard throughout the week. First, hardly anyone seems to be talking about health as a component of the post-2015 development agenda—except the global health community. Although health remains a critical piece of the priorities coming from UN Member States—such as in the outcome document Member States endorsed during UNGA—the discussions among broader civil society groups last week tended to focus on other topics, like human rights, water and sanitation, environmental degradation, and inclusivity. R&D for new, innovative health tools will be essential to achieve any international development goals. Credit: PATH/Evelyn Hockstein That said, there does seem to be broad recognition there will be a health goal included in the post-2015 agenda, as well as more clarity on how such a goal might be framed. Though it’s unclear what the ultimate language will look like, there seems to be general accord that there will be one overarching health goal with related targets.These targets will call out such topics as: Universal health coverage. Non-communicable diseases. Child health. Maternal mortality. HIV and AIDS. Tuberculosis. Malaria. What is less clear is how innovation will fit into this goal. As we’ve said before, research and development (R&D) for new, innovative health tools will be essential to achieve any international development goals, as well as to enable more equitable and sustainable improvements across health services and health outcomes. Additionally, the discussions in New York raise some red flags about perceptions of the private sector—particularly, that some stakeholders view private industry as a monolith with only negative objectives. There is admittedly a spectrum of intentions when it comes to private industry and health. But when it comes to health R&D, it must be recognized that partnerships between the public and private sectors have been key to moving forward major public health successes: from established products like treatments for HIV and AIDS to new products such as a vaccine to prevent childhood diarrhea. Though we must determine how the private sector can be engaged in appropriate ways in discussions on a post-2015 development agenda, we certainly can’t exclude our private sector partners altogether from discussions about future sustainable development goals and plans to achieve them. GHTC will continue to follow the debates and engage in discussions alongside the rest of the health and development community. Next up: the Open Working Group on Sustainable Development Goals’ meetings in November and December, when the theme of science and technology will be discussed among many other topics.
PATH/Patrick McKern
September 26, 2013

Research Roundup: What we’re reading this week

Written by Kim Lufkin / GHTC
Read time:
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week. In a new opinion piece, Reps. Albio Sires (D-NJ) and Mario Diaz-Balart (R-FL) write about the need to sustain US investments in research and development for global health tools to prevent the spread of disease both in the United States and abroad. The International Federation of Pharmaceutical Manufacturers & Associations is calling for increased public-private sector engagement to accelerate progress toward the Millennium Development Goals. The group is also stressing that partnerships be central components of the post-2015 development agenda. Rep. Barbara Lee (D-CA) recently introduced a bill that aims to stop the spread of HIV around the world. The bill, called the Ending the HIV and AIDS Epidemic Act of 2013 (HR 3117), includes a focus on research to create new HIV and AIDS treatment and prevention tools. A new investment fund launched this week that will allow individuals and institutional investors the opportunity to finance the development of late-stage global health technologies. The HOOKVAC consortium has been awarded a grant from the European Commission to expand the Sabin Vaccine Institute Product Development Partnership’s work to develop and test a vaccine for human hookworm. Under the grant, the HOOKVAC consortium will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.